Antidiabetogenic and antioxidative effects of octaphlorethol a isolated from the brown algae Ishige foliacea in streptozotocin-induced diabetic mice

Lee, Seung‐Hong; Kang, Ning; Kim, Eun-A; Heo, Soo‐Jin; Moon, Sang-Ho; Jeon, Byong-Tae; Jeon, You‐Jin

doi:10.1007/s10068-014-0173-6

Cited by 14 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2009 ; Lee et al. 2014 ). These studies have shown similar results with our research that phlorotannin from brown algae may have a beneficial effect on controlling postprandial glucose levels.…”

Section: Discussionmentioning

confidence: 99%

A phlorotannin constituent of Ecklonia cava alleviates postprandial hyperglycemia in diabetic mice

Lee

Lee²,

Han

2017

Pharmaceutical Biology

View full text Add to dashboard Cite

Context: 2,7″-Phloroglucinol-6,6′-bieckol is a type of phlorotannin isolated from brown algae, Ecklonia cava Kjellman (Phaeophyceae; Laminareaceae). 2,7″-Phloroglucinol-6,6′-bieckol mediates antioxidant activities. However, there has been no research on improving postprandial hyperglycaemia using 2,7″-phloroglucinol-6,6′-bieckol.Objective: This study investigated the inhibitory effects of 2,7″-phloroglucinol-6,6′-bieckol on activities of α-glucosidase and α-amylase as well as its alleviating effect on postprandial hyperglycaemia in streptozotocin-induced diabetic mice.Materials and methods: α-Glucosidase and α-amylase inhibitory assays were carried out. The effect of 2,7″-phloroglucinol-6,6′-bieckol on hyperglycaemia after a meal was measured by postprandial blood glucose in streptozotocin-induced diabetic and normal mice. The mice were treated orally with soluble starch (2 g/kg BW) alone (control) or with 2,7″-phloroglucinol-6,6′-bieckol (10 mg/kg bw) or acarbose (10 mg/kg BW) dissolved in 0.2 mL water. Blood samples were taken from tail veins at 0, 30, 60, and 120 min and blood glucose was measured by a glucometer.Results: 2,7″-Phloroglucinol-6,6′-bieckol showed higher inhibitory activities than acarbose, a positive control against α-glucosidase and α-amylase. The IC50 values of 2,7″-phloroglucinol-6,6′-bieckol against α-glucosidase and α-amylase were 23.35 and 6.94 μM, respectively, which was found more effective than observed with acarbose (α-glucosidase IC50 of 130.04 μM; α-amylase IC50 of 165.12 μM). In normal mice, 2,7″-phloroglucinol-6,6′-bieckol significantly suppressed the postprandial hyperglycaemia caused by starch. The 2,7″-phloroglucinol-6,6′-bieckol administration group (2349.3 mmol·min/L) had a lower area under the curve (AUC) glucose response than the control group (2690.83 mmol·min/L) in diabetic mice.Discussion and conclusion: 2,7″-Phloroglucinol-6,6′-bieckol might be used as an inhibitor of α-glucosidase and α-amylase as well as to delay absorption of dietary carbohydrates.

show abstract

Section: Discussionmentioning

confidence: 99%

A phlorotannin constituent of Ecklonia cava alleviates postprandial hyperglycemia in diabetic mice

Lee

Lee²,

Han

2017

Pharmaceutical Biology

View full text Add to dashboard Cite

show abstract

“…It also suppressed apoptosis and was associated with reductions in pro-apoptotic Bax and cleaved caspase-3 expressions and elevated anti-apoptotic BclxL expression. 163 Lee et al also concluded that the mechanism of OPA activity might involve the activation of AMPK which leads to glucose uptake in skeletal muscle through Glut4-mediated and inhibition of PEPCK and G6Pase activity in the liver leading to the suppression of gluconeogenesis. Thus, the findings provide a new opportunity through the clinical application of OPA as a potential anti-diabetic agent.…”

Section: Secondary Metabolitesmentioning

confidence: 99%

Hypoglycaemic Molecules for the Management of Diabetes Mellitus from Marine Sources

Chellappan,

Chellian,

Rahmah

et al. 2023

DMSO

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a chronic metabolic disorder recognized as a major health problem globally. A defective insulin activity contributes to the prevalence and expansion of DM. Treatment of DM is often hampered by limited options of conventional therapies and adverse effects associated with existing procedures. This has led to a spike in the exploration for potential therapeutic agents from various natural resources for clinical applications. The marine environment is a huge store of unexplored diversity of chemicals produced by a multitude of organisms. To date, marine microorganisms, microalgae, macroalgae, corals, sponges, and fishes have been evaluated for their anti-diabetic properties. The structural diversity of bioactive metabolites discovered has shown promising hypoglycaemic potential through in vitro and in vivo screenings via various mechanisms of action, such as PTP1B, α-glucosidase, α-amylase, β-glucosidase, and aldose reductase inhibition as well as PPAR alpha/gamma dual agonists activities. On the other hand, hypoglycaemic effect is also shown to be exerted through the balance of antioxidants and free radicals. This review highlights marine-derived chemicals with hypoglycaemic effects and their respective mechanisms of action in the management of DM in humans.

show abstract

“…In addition to dietary management, hypoglycemic drugs are often used to treat T2DM [ 8 ]. However, the available hypoglycemic reagents have inadequate efficacy and some serious mechanism-based side effects, including hypoglycemia, gastrointestinal stimulation, and edema [ 12 , 13 ]. Owing to thesevere side-effects of synthetic hypoglycemic drugs, more effective and safer hypoglycemic agents from natural sources are greatly needed [ 14 , 15 , 16 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Bioactives of Momordica charantia as Potential Anti-Diabetic/Hypoglycemic Agents

Zeng

et al. 2022

Molecules

View full text Add to dashboard Cite

Momordica charantia L., a member of the Curcubitaceae family, has traditionally been used as herbal medicine and as a vegetable. Functional ingredients of M. charantia play important roles in body health and human nutrition, which can be used directly or indirectly in treating or preventing hyperglycemia-related chronic diseases in humans. The hypoglycemic effects of M. charantia have been known for years. In this paper, the research progress of M. charantia phytobioactives and their hypoglycemic effects and related mechanisms, especially relating to diabetes mellitus, has been reviewed. Moreover, the clinical application of M. charantia in treating diabetes mellitus is also discussed, hoping to broaden the application of M. charantia as functional food.

show abstract

Antidiabetogenic and antioxidative effects of octaphlorethol a isolated from the brown algae Ishige foliacea in streptozotocin-induced diabetic mice

Cited by 14 publications

References 23 publications

A phlorotannin constituent of Ecklonia cava alleviates postprandial hyperglycemia in diabetic mice

A phlorotannin constituent of Ecklonia cava alleviates postprandial hyperglycemia in diabetic mice

Hypoglycaemic Molecules for the Management of Diabetes Mellitus from Marine Sources

Bioactives of Momordica charantia as Potential Anti-Diabetic/Hypoglycemic Agents

Contact Info

Product

Resources

About